?????Metastatic bone disease (MBD) is a major source of morbidity and mortality for patients afflicted with advanced cancers of the breast, prostate, lung, kidney, thyroid as well as myeloma and others. With a prevalence of cancer in US at about 5 million cases annually, well over 1.2 million new cases of cancer are diagnosed per annum. About half of these cases will go on to involve the skeleton. As of 2007, the cost to society was approximately $12.6 billion and made up almost 20% of societal cancer costs as estimated by the National Institutes of Health (Schulman KL,Kohles. Economic burden of metastatic bone disease in the U.S. Cancer. 2007 Jun 1;109(11):2334-42). These numbers are continuing to arise as the population ages. Accordingly, MBD is a major health care problem in our country and also the world. While progress has been made in the medical management, the orthopaedic surgeon, whether general or advanced trained, will be asked to manage a growing number of patients with MBD in her practice. Technological advancements in the surgical palliation and stabilization are continually evolving. For the orthopaedic oncologist, the majority of his or her practice is involved with the complex management of the spectrum of nefarious neoplasms afflicting the musculoskeletal system. For the general orthopaedist, he too will face a growing number of patients needing his skill set to enable their remaining quality of life and to manage/prevent catastrophic skeletal related events (SREs). Furthermore, tremendous advancements have been made in the medical management of MBD, from bisphosphonates to targeted therapies, patients are living longer and are being enabled to pursue high levels of activity.??
- ISBN: 978-1-4614-5661-2
- Editorial: Springer
- Encuadernacion: Cartoné
- Páginas: 400
- Fecha Publicación: 08/10/2015
- Nº Volúmenes: 1
- Idioma: Inglés